(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 September 2011 (01.09.2011)

PCT

(10) International Publication Number
WO 2011/104687 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 37/00* (2006.01)
C12N 15/13 (2006.01) *A61P 3/10* (2006.01)
A61K 39/395 (2006.01) *A61P 37/06* (2006.01)

(21) International Application Number:
PCT/IB2011/050792

(22) International Filing Date:
24 February 2011 (24.02.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/307,670 24 February 2010 (24.02.2010) US
61/438,205 31 January 2011 (31.01.2011) US

(71) Applicant *(for all designated States except US)*: **RINAT NEUROSCIENCE CORPORATION** [US/US]; 230 East Grand Avenue, South San Francisco, CA 94080 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **LIN, Chia-Yang** [US/US]; Rinat Neuroscience Corporation 230 East, Grand Avenue, South San Francisco, CA 94080 (US). **LEE, Li-Fen** [CN/US]; Rinat Neuroscience Corporation 230 East, Grand Avenue, South San Francisco, CA 94080 (US). **ZHAI, Wenwu** [GB/US]; Rinat Neuroscience Corporation 230 East, Grand Avenue, South San Francisco, CA 94080 (US).

(74) Agents: **KLEIMAN, Gabriel L.** et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS

(57) Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.

WO 2011/104687 A1